title: Effect of several 5-hydroxytryptamine(1A) receptor ligands on the micturition reflex in rats: comparison with WAY 100635.
abstract: Several novel N-arylpiperazine derivatives were synthesized and tested for their 1) affinity and functional activity on 5-hydroxytryptamine(1A) (5-HT(1A)) receptors in vitro; 2) activity in models predictive of antagonism at somatodendritic and postsynaptic 5-HT(1A) receptors; and 3) effects on the micturition reflex in anesthetized and conscious rats. These studies also included 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine hydrobromide (NAN 190), 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4, 5]decane-7,9-dione dihydrochloride (BMY 7378), and N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl-N-(2-pyridinyl)cyclohex anecarboxamide (WAY 100635). Almost all compounds were found to be potent and selective for the human recombinant 5-HT(1A) receptor, with K(i) values in the nanomolar range. [(35)S]GTPgammaS binding in HeLa cells expressing the recombinant human 5-HT(1A) receptor allowed classification of the compounds into neutral antagonists and partial agonists. Almost all neutral antagonists were active in blocking 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT)-induced forepaw treading in rats (postsynaptic model) and hypothermia in mice (somatodendritic model) with the same potency, whereas compounds showing partial agonistic activity were active in the postsynaptic model but were inactive, or poorly active, in the somatodendritic model. Neutral antagonists potently inhibited volume-induced bladder-voiding contractions in anesthetized rats. Contractions were completely blocked, and the disappearance of bladder contractions lasted 7 to 13 min after the highest doses tested. Furthermore, neutral antagonists increased bladder volume capacity in conscious rats during continuous transvesical cystometry, whereas micturition pressure was only slightly, and not dose-dependently, reduced. Partial agonists were inactive or poorly active, inducing a disappearance time of bladder contractions that did not exceed 6 min in anesthetized rats, and failing to increase bladder volume capacity in conscious rats. These findings indicate that only neutral 5-HT(1A) receptor antagonists are endowed with inhibitory effects on the bladder.
authors.affiliation: Pharmaceutical Research and Development Division, Recordati S.p.A., Milan, Italy. TESTA.R@RECORDATI.it
authors.forename: R
authors.initials: R
authors.lastname: Testa
authors.forename: L
authors.initials: L
authors.lastname: Guarneri
authors.forename: E
authors.initials: E
authors.lastname: Poggesi
authors.forename: P
authors.initials: P
authors.lastname: Angelico
authors.forename: C
authors.initials: C
authors.lastname: Velasco
authors.forename: M
authors.initials: M
authors.lastname: Ibba
authors.forename: A
authors.initials: A
authors.lastname: Cilia
authors.forename: G
authors.initials: G
authors.lastname: Motta
authors.forename: C
authors.initials: C
authors.lastname: Riva
authors.forename: A
authors.initials: A
authors.lastname: Leonardi
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D006367:HeLa Cells / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010879:Piperazines / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000378:metabolism / Q000502:physiology*; D044263:Receptors, Serotonin, 5-HT1; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D012702:Serotonin Antagonists / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D001743:Urinary Bladder / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D014554:Urination / Q000187:drug effects* / Q000502:physiology
chemical_list: D008024:Ligands; D010879:Piperazines; D011725:Pyridines; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D012702:Serotonin Antagonists; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide